Synergizing sodium-dependent glucose transporter inhibitors with dipeptidyl-peptidase 4 inhibitor and metformin: a novel approach to diabetes management in Indi

Background: The rising prevalence of diabetes in India necessitates effective and targeted management strategies. This article explores the efficacy of synergistic action of key antidiabetic agents, including metformin, sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, and dipeptidyl-peptidase-4 (DPP-4) inhibitors, in a fixed dose combination. Methods: The current survey obtained the opinion of the health care professionals (HCPs) on the benefits and significance of the triple fixed dose combinations (FDCs) of dapagliflozin, sitagliptin, and metformin in type 2 diabetes mellitus (T2DM) management. Results: The poll indicates that ~97% of the healthcare practitioners agreeing on the importance of achieving better time in range with the FDC and the potential benefits of early initiation of the FDC for improved glycemic control and cardio-renal outcomes. Majority of HCPs (77%) express confidence in the safety profile of the combination in T2DM. Almost all (99%) of the HCPs agree on the need for collating real-world data from HCPs to understand the effectiveness of FDC in India and for devising evidence based strategies. Conclusions: The triple FDC of dapagliflozin, sitagliptin, and metformin stands out as a promising approach for diabetes management. The study also underscores the importance of conducting extensive, large scale real-world studies to gather more data, contributing to evidence based strategies for diabetes management in the Indian population.